Literature DB >> 31066006

Down-regulation expression of TGFB2-AS1 inhibits the proliferation, migration, invasion and induces apoptosis in HepG2 cells.

Wenrong Liu1, Ruiping Huai1, Yin Zhang1, Shuquan Rao1, Lili Xiong1, Ruofan Ding1, Canquan Mao1, Wenqing Zhao2, Tao Hao2, Qingqing Huang1, Zhiyun Guo3.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the leading cause of cancer mortality and without effective prognosis. Previous study has been confirmed that the abnormal expression of long non-coding RNAs (lncRNAs) TGFB2-AS1 was involved in tumorigenesis. However, the biological functions of TGFB2-AS1 in hepatocellular carcinoma (HCC) remain largely unclear.
OBJECTIVE: We comprehensively assess the clinical significance of TGFB2-AS1 and investigate the biological functions of TGFB2-AS1 on HCC HepG2 cells.
METHODS: We firstly confirmed the expression of TGFB2-AS1 between tumor and normal tissues using public available transcriptome data. We analyzed the clinical significance of TGFB2-AS1 using the TCGA HCC datasets. The biological functions of TGFB2-AS1 on HCC HepG2 cells were explored by multiple in vitro assays.
RESULTS: We found that TGFB2-AS1 was remarkably increased in HCC tissues (P = 0.00148) and exhibited a potential predictive marker for HCC, with an area under curve (AUC) of 0.708 (P = 0.0034) using the fifty pairs of matched HCC tissues of TCGA. Besides, higher expression of TGFB2-AS1 in HCC tissues was identified as being positively associated with advanced tumor (P = 0.012) and disease stage (P = 0.009) in 355 HCC cases using independent sample nonparametric test. Downregulation of TGFB2-AS1 expression significantly restrained proliferation (P < 0.01) and impaired colony formation (P < 0.05). Furthermore, TGFB2-AS1 depletion remarkably promoted the apoptosis of HepG2 cells (P < 0.05) and inhibited migration and invasion (P < 0.01).
CONCLUSION: Taken together, these findings suggested that TGFB2-AS1 might serve as a potential therapeutic target for HCC.

Entities:  

Keywords:  Apoptosis; Bioinformatics; Hepatocellular carcinoma; Long non-coding RNA; Migration; Proliferation

Mesh:

Substances:

Year:  2019        PMID: 31066006     DOI: 10.1007/s13258-019-00826-6

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  20 in total

Review 1.  The emerging role of lncRNAs in cancer.

Authors:  Maite Huarte
Journal:  Nat Med       Date:  2015-11       Impact factor: 53.440

Review 2.  Hepatocellular carcinoma review: current treatment, and evidence-based medicine.

Authors:  Ali Raza; Gagan K Sood
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells.

Authors:  Sachi Horibata; Tommy V Vo; Venkataraman Subramanian; Paul R Thompson; Scott A Coonrod
Journal:  J Vis Exp       Date:  2015-05-20       Impact factor: 1.355

4.  HOX Antisense lincRNA HOXA-AS2 Promotes Tumorigenesis of Hepatocellular Carcinoma.

Authors:  Fuqiang Wang; Huili Yang; Zhigang Deng; Yongjie Su; QinLiang Fang; Zhenyu Yin
Journal:  Cell Physiol Biochem       Date:  2016-11-18

5.  Long noncoding RNA NKILA enhances the anti-cancer effects of baicalein in hepatocellular carcinoma via the regulation of NF-κB signaling.

Authors:  Xiaolan Yu; Wei Tang; Yingcheng Yang; Li Tang; Rongyang Dai; Bangming Pu; Chunhong Feng; Jiyi Xia
Journal:  Chem Biol Interact       Date:  2018-02-23       Impact factor: 5.192

6.  Transcriptome profiling analysis of differentially expressed mRNAs and lncRNAs in HepG2 cells treated with peptide 9R-P201.

Authors:  Wenrong Liu; Ruofan Ding; Yiming Zhang; Canquan Mao; Ran Kang; Junhua Meng; Qingqing Huang; Lili Xiong; Zhiyun Guo
Journal:  Biotechnol Lett       Date:  2017-07-31       Impact factor: 2.461

7.  Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.

Authors:  Cheng-Jun Sui; Yan-Ming Zhou; Wei-Feng Shen; Bing-Hua Dai; Jiong-Jiong Lu; Min-Feng Zhang; Jia-Mei Yang
Journal:  J Mol Med (Berl)       Date:  2016-07-05       Impact factor: 4.599

8.  Long noncoding RNAs and hepatocellular carcinoma.

Authors:  James F Collins
Journal:  Gastroenterology       Date:  2014-12-18       Impact factor: 22.682

9.  A comprehensive genome-wide analysis of long noncoding RNA expression profile in hepatocellular carcinoma.

Authors:  Hongxia Cui; Yunxing Zhang; Qiujie Zhang; Wenming Chen; Haibo Zhao; Jun Liang
Journal:  Cancer Med       Date:  2017-10-18       Impact factor: 4.452

10.  Effects of LncRNA-HOST2 on cell proliferation, migration, invasion and apoptosis of human hepatocellular carcinoma cell line SMMC-7721.

Authors:  Run-Tian Liu; Jing-Lin Cao; Chang-Qing Yan; Yang Wang; Cong-Jing An; Hai-Tao Lv
Journal:  Biosci Rep       Date:  2017-04-20       Impact factor: 3.840

View more
  5 in total

1.  Polysome-associated lncRNAs during cardiomyogenesis of hESCs.

Authors:  Isabela Tiemy Pereira; Lucia Spangenberg; Guillermo Cabrera; Bruno Dallagiovanna
Journal:  Mol Cell Biochem       Date:  2020-03-03       Impact factor: 3.396

2.  Development of six immune-related lncRNA signature prognostic model for smoking-positive lung adenocarcinoma.

Authors:  Dajie Zhou; Jing Wang; Xiangdong Liu
Journal:  J Clin Lab Anal       Date:  2022-05-13       Impact factor: 3.124

Review 3.  The Impact of Long Non-Coding RNAs in the Pathogenesis of Hepatocellular Carcinoma.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Bashdar Mahmud Hussen; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

Review 4.  Regulatory Roles of Noncoding RNAs in the Progression of Gastrointestinal Cancers and Health Disparities.

Authors:  Aditi Kulkarni; Sharan Gayathrinathan; Soumya Nair; Anamika Basu; Taslim A Al-Hilal; Sourav Roy
Journal:  Cells       Date:  2022-08-07       Impact factor: 7.666

5.  Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer.

Authors:  Wenchang Lv; Yufang Tan; Xiaomei Zhou; Qi Zhang; Jun Zhang; Yiping Wu
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.